Ligand Pharmaceuticals Incorporated Market Cap ($6.36 Billion)
Market Cap & Net Worth: Ligand Pharmaceuticals Incorporated (LGND)
Ligand Pharmaceuticals Incorporated market cap. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has a market capitalization of $6.36 Billion ($6.36 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2953 globally and #1074 in its home market, demonstrating a 4.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ligand Pharmaceuticals Incorporated's stock price $322.75 by its total outstanding shares 21700000 (21.70 Million).
Ligand Pharmaceuticals Incorporated Market Cap History (2015–2026)
Ligand Pharmaceuticals Incorporated market cap history from 2015 to 2026. Data shows growth from $1.47 Billion to $7.00 Billion (16.78% CAGR). Check current stock price of Ligand Pharmaceuticals Incorporated for real-time trading data and today's change.
Index Memberships
Ligand Pharmaceuticals Incorporated is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.24% | #72 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.02% | #334 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.35% | #50 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.56 Trillion | 0.17% | #38 of 602 |
Weight: Ligand Pharmaceuticals Incorporated's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ligand Pharmaceuticals Incorporated Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ligand Pharmaceuticals Incorporated's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Ligand Pharmaceuticals Incorporated (LGND) cash conversion ratio for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
15.30x
Ligand Pharmaceuticals Incorporated's market cap is 15.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
32.97x
Ligand Pharmaceuticals Incorporated's market cap is 32.97 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.38 Billion | $108.97 Million | -$1.64 Million | 12.62x | N/A |
| 2017 | $1.85 Billion | $141.10 Million | $12.56 Million | 13.14x | 147.63x |
| 2018 | $1.84 Billion | $251.45 Million | $143.32 Million | 7.31x | 12.82x |
| 2019 | $1.41 Billion | $120.28 Million | $629.30 Million | 11.74x | 2.24x |
| 2020 | $1.35 Billion | $163.56 Million | -$2.98 Million | 8.23x | N/A |
| 2021 | $2.09 Billion | $241.54 Million | $57.14 Million | 8.66x | 36.59x |
| 2022 | $1.45 Billion | $196.25 Million | -$33.36 Million | 7.39x | N/A |
| 2023 | $1.55 Billion | $131.31 Million | $52.15 Million | 11.80x | 29.72x |
| 2024 | $2.33 Billion | $167.13 Million | -$4.03 Million | 13.91x | N/A |
| 2025 | $4.10 Billion | $268.09 Million | $124.45 Million | 15.30x | 32.97x |
Competitor Companies of LGND by Market Capitalization
Companies near Ligand Pharmaceuticals Incorporated in the global market cap rankings as of October 31, 2026. See Ligand Pharmaceuticals Incorporated net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Ligand Pharmaceuticals Incorporated by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Ligand Pharmaceuticals Incorporated (2015–2026)
Market capitalization of Ligand Pharmaceuticals Incorporated from 2015 to today. Between 2015 and today, Ligand Pharmaceuticals Incorporated's market cap moved from $1.47 Billion to $ 7.00 Billion, with a yearly change of 16.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.00 Billion | +70.70% |
| 2025 | $4.10 Billion | +76.45% |
| 2024 | $2.33 Billion | +50.03% |
| 2023 | $1.55 Billion | +6.92% |
| 2022 | $1.45 Billion | -30.67% |
| 2021 | $2.09 Billion | +55.31% |
| 2020 | $1.35 Billion | -4.64% |
| 2019 | $1.41 Billion | -23.15% |
| 2018 | $1.84 Billion | -0.90% |
| 2017 | $1.85 Billion | +34.76% |
| 2016 | $1.38 Billion | -6.28% |
| 2015 | $1.47 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Ligand Pharmaceuticals Incorporated was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.36 Billion USD |
| MoneyControl | $6.36 Billion USD |
| MarketWatch | $6.36 Billion USD |
| marketcap.company | $6.36 Billion USD |
| Reuters | $6.36 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help figh… Read more